2.1. Study setting
This study was designed as a single-blind, parallel-group, randomized controlled trial and was conducted in a tertiary university hospital in the Republic of Korea from December 2021 to April 2023. This study was reviewed and approved by the Institutional Review Board of Wonju Severance Christian Hospital (CR321106, approval date: October 14, 2021). This study was registered with the Clinical Research Information Service, Republic of Korea (KCT0006719, registered on November 08, 2021) and reported in accordance with the Consolidated Standards of Reporting Trials guidelines. Candidates for enrollment were informed about the study via an informed consent form. Only those candidates that provided informed consent were considered and the procedures were conducted in accordance with the Helsinki Declaration.